Latest Updates (2026)
Curated latest news on drug approvals, regulatory updates, M&A deals, and industry developments in the Indian pharmaceutical sector.
1. Sun Pharma Acquires US-Based Organon for $11.75 Billion
Date: April 26, 2026
India’s largest pharmaceutical company, Sun Pharmaceutical Industries, announced the acquisition of New Jersey-based Organon & Co in an all-cash deal valued at $11.75 billion, including debt. This marks India’s biggest-ever overseas pharma acquisition and will propel Sun Pharma into the top 25 global pharmaceutical firms with projected revenues of $12.4 billion.
The acquisition grants Sun Pharma access to Organon’s biosimilars arm, making it the world’s seventh-biggest biosimilar company and a “top 3 company in global Women’s Health”. The deal includes assuming Organon’s $8.6 billion debt and adds over $1.6 billion in North American sales.
2. Generic Semaglutide Patent Expires in India – Multiple Launches
Date: March 20, 2026
The core semaglutide patent expired in India on March 20, 2026, immediately drawing in generic manufacturers with prices starting as low as ₹220 per shot. Multiple Indian pharma companies including Dr. Reddy’s, Zydus, Alkem, Sun Pharma, and Glenmark launched generic semaglutide products.
Sun Pharma plans to introduce generic semaglutide under the brand name Noveltreat, while Dr. Reddy’s received approval for oral semaglutide tablets (3mg, 7mg, 14mg) for type-2 diabetes. Monthly treatment costs are predicted to plummet by 70–90% to roughly ₹3,000–₹6,000.
3. Dr. Reddy’s Debuts Semaglutide Pill at ₹99 Starting Price
Date: January 2026
Dr. Reddy’s Laboratories launched the generic semaglutide pill starting at just ₹99, making obesity and diabetes treatment dramatically more affordable for Indian patients. The formulation was clinically evaluated in a head-to-head comparative study in India, establishing non-inferiority to Novo Nordisk’s oral semaglutide (Rybelsus brand).
The company received final approval from India’s drug regulator (CDSCO) to manufacture and sell generic versions of semaglutide tablets, even as Novo Nordisk battles Indian drugmakers over alleged patent infringement.
Source: https://pharma.economictimes.indiatimes.com
4. Zydus’ Baddi Facility Gets FDA Warning Letter
Date: May 2026
Zydus Lifesciences’ Baddi facility received a warning letter from the US FDA, according to the company. The Warning Letter was issued in response to a request for records under the Federal Food, Drug, and Cosmetics Act and does not pertain to any on-site inspection by the FDA.
Additionally, the Delhi High Court directed CDSCO to decide on patient safety concerns regarding Zydus’ semaglutide approval. Zydus plans to launch innovative semaglutide injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy.
Source: https://pharma.economictimes.indiatimes.com
5. Pfizer Launches Cancer Bispecific Elranatamab in India
Date: May 2026
Pfizer launched its cancer bispecific drug Elranatamab in India for relapsed or refractory multiple myeloma patients. This marks a significant expansion of Pfizer’s oncology portfolio in the Indian market.
The launch represents one of the latest innovative cancer treatments becoming available in India, supporting the country’s growing access to advanced oncology therapies.
Source: https://pharma.economictimes.indiatimes.com
6. Serum Institute of India to Manufacture Oxford Ebola Vaccine
Date: May 2026
The Serum Institute of India (SII) announced it will manufacture the Oxford Ebola vaccine, strengthening India’s position in global vaccine production. Moderna and other groups also received $60 million to develop Ebola vaccine.
Merck executives said the company is discussing use of its COVID antiviral drug Lagevrio amid Ebola outbreak. This development highlights India’s critical role in global infectious disease vaccine manufacturing.
Source: https://pharma.economictimes.indiatimes.com
7. Wockhardt’s Novel Antibiotic Zaynich Wins Marketing Approval in India
Date: May 2026
Wockhardt’s novel antibiotic Zaynich (cefepime and zidebactam) won marketing approval in India, with blockbuster potential lifting Wockhardt’s long-term outlook. The drug is expected to achieve yearly sales of $1.5–2 billion in 6 years.
Zaynich received FDA approval on May 29, 2026, to treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms.
Source: https://pharma.economictimes.indiatimes.com
8. Delhi HC Allows Intas to Sell Cancer Drug Bevatas, Sets Aside Sun Pharma Order
Date: May 2026
The Delhi High Court allowed Intas Pharmaceuticals to sell its cancer drug Bevatas, setting aside a previous order that favored Sun Pharma. This decision impacts the competitive landscape for biosimilar cancer treatments in India.
The ruling allows Intas to continue marketing Bevatas, a biosimilar version of Roche’s Avastin, for cancer treatment in India.
Source: https://pharma.economictimes.indiatimes.com
9. Edgewise to Sell Muscle Dystrophy Business to Servier for Up to $2.65 Billion
Date: May 2026
Edgewise Therapeutics announced it will sell its muscle dystrophy business to Servier for up to $2.65 billion. This deal represents a major M&A transaction in the rare disease therapeutics sector.
The acquisition strengthens Servier’s portfolio in neuromuscular disorders while providing Edgewise with significant capital to fund other research and development programs.
Source: https://pharma.economictimes.indiatimes.com
10. Americans’ Prescription Drug Spending to Top $1 Trillion in 2026
Date: June 2026
Prescription drug spending in the United States is on a trajectory to top $1 trillion in 2026, fueled primarily by spending on weight-loss drugs (GLP-1s). GLP-1s made up eight of every 100 prescriptions filled in March 2026.
CMS proposed faster, more transparent drug prior authorization rules, while Medicare’s GLP-1 bridge model expands obesity drug access. This trend significantly impacts Indian pharma companies producing generic semaglutide and other GLP-1 therapies.
Source: https://paladinpointofsale.com/2026/05/26/pharmacy-news-june-2026/